文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

血小板减少患者中心静脉导管置入前的血小板输注

Platelet Transfusion before CVC Placement in Patients with Thrombocytopenia.
PubMed 文献 · N Engl J Med · 2023-01-01
一句话结论血小板计数1万-5万/mm³患者超声引导CVC置入前不预防性输注血小板未达到非劣效界值,且CVC相关出血事件多于预防性输注。

这项多中心随机对照非劣效性试验纳入血小板计数1万-5万/mm³、在血液科病房或ICU接受治疗的患者,比较超声引导CVC置入前预防性输注1单位血小板与不输注。主要终点为2-4级导管相关出血,非劣效界值为90%CI相对风险上限3.5。不输注组2-4级出血风险为输注组的2.45倍(90%CI 1.27-4.70),未达到非劣效界值;3-4级出血相对风险2.43(95%CI 0.75-7.93)。不输注策略每次置管净节省410美元,但CVC相关出血事件更多。

要点

  • 血小板计数1万-5万/mm³患者超声引导CVC置入前不预防性输注血小板,2-4级导管相关出血相对风险为输注组的2.45倍(90%CI 1.27-4.70),未达到预设非劣效界值。
  • 3-4级导管相关出血:输注组4/188例(2.1%)vs 不输注组9/185例(4.9%),相对风险2.43(95%CI 0.75-7.93),未达统计学显著。
  • 共观察15例不良事件,其中13例为3级导管相关出血(输注组4例、不输注组9例),均归类为严重不良事件。
  • 不输注预防性血小板每次置管净节省410美元,但以更多CVC相关出血事件为代价。
  • 该研究针对超声引导下CVC置入、血小板计数1万-5万/mm³的血液科病房或ICU患者。

适用人群与场景

  • 严重血小板减少(血小板计数1万-5万/mm³)、在血液科病房或ICU接受治疗、需超声引导下中心静脉导管(CVC)置入的患者。

诊断标准与关键阈值

  • 血小板计数界值:10,000至50,000每立方毫米。
  • 主要终点为导管相关出血2-4级;关键次要终点为3级或4级出血。
  • 非劣效界值:90%置信区间相对风险上限为3.5。

处置流程与药物剂量

  • 超声引导下CVC置入前,随机接受1单位预防性血小板输注或不输注血小板。

研究设计与关键结果

  • 多中心、随机、对照、非劣效性试验,纳入338例患者共373次CVC置入,符合方案主要分析纳入373次置入。
  • 2-4级导管相关出血:输注组9/188例(4.8%)vs 不输注组22/185例(11.9%),相对风险2.45(90%CI 1.27-4.70)。
  • 3-4级导管相关出血:输注组4/188例(2.1%)vs 不输注组9/185例(4.9%),相对风险2.43(95%CI 0.75-7.93)。
  • 共15例不良事件,其中13例为3级导管相关出血(输注组4例、不输注组9例),均归类为严重不良事件。
  • 不输注预防性血小板每次置管净节省410美元。

证据类型、等级与局限

  • 证据类型:多中心随机对照非劣效性试验(PACER,荷兰试验注册号NL5534),由ZonMw资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:血小板计数1万-5万/mm³患者超声引导CVC置入前不预防性输注血小板未达到预设非劣效界值,且CVC相关出血事件多于预防性血小板输注。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Transfusion guidelines regarding platelet-count thresholds before the placement of a central venous catheter (CVC) offer conflicting recommendations because of a lack of good-quality evidence. The routine use of ultrasound guidance has decreased CVC-related bleeding complications.

METHODS: In a multicenter, randomized, controlled, noninferiority trial, we randomly assigned patients with severe thrombocytopenia (platelet count, 10,000 to 50,000 per cubic millimeter) who were being treated on the hematology ward or in the intensive care unit to receive either one unit of prophylactic platelet transfusion or no platelet transfusion before ultrasound-guided CVC placement. The primary outcome was catheter-related bleeding of grade 2 to 4; a key secondary outcome was grade 3 or 4 bleeding. The noninferiority margin was an upper boundary of the 90% confidence interval of 3.5 for the relative risk.

RESULTS: We included 373 episodes of CVC placement involving 338 patients in the per-protocol primary analysis. Catheter-related bleeding of grade 2 to 4 occurred in 9 of 188 patients (4.8%) in the transfusion group and in 22 of 185 patients (11.9%) in the no-transfusion group (relative risk, 2.45; 90% confidence interval [CI], 1.27 to 4.70). Catheter-related bleeding of grade 3 or 4 occurred in 4 of 188 patients (2.1%) in the transfusion group and in 9 of 185 patients (4.9%) in the no-transfusion group (relative risk, 2.43; 95% CI, 0.75 to 7.93). A total of 15 adverse events were observed; of these events, 13 (all grade 3 catheter-related bleeding [4 in the transfusion group and 9 in the no-transfusion group]) were categorized as serious. The net savings of withholding prophylactic platelet transfusion before CVC placement was $410 per catheter placement.

CONCLUSIONS: The withholding of prophylactic platelet transfusion before CVC placement in patients with a platelet count of 10,000 to 50,000 per cubic millimeter did not meet the predefined margin for noninferiority and resulted in more CVC-related bleeding events than prophylactic platelet transfusion. (Funded by ZonMw; PACER Dutch Trial Register number, NL5534.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. van Baarle FLF, van de Weerdt EK, van der Velden WJFM, et al. Platelet Transfusion before CVC Placement in Patients with Thrombocytopenia. N Engl J Med. 2023. PMID: 37224197. doi:10.1056/NEJMoa2214322

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。